CASE REPORT OF UNDIFFERENTIATED EMBRYONAL SARCOMA OF A LIVER MISDIAGNOSED WITH FALLOPIAN TUBE CARCINOMA METASTASIS

Jin Ha Kim, MD, Tae Hwa Lee, MD, Heong Yeol Kim, MD, Won Gyu Kim, MD, Sung Han Kim, MD
Department of Obstetrics and Gynecology, Kosin University College of Medicine, Busan, Korea

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare but aggressive primary tumor of the liver occurring most frequently in childhood. Its frequency in the adult population is extremely low. A 41-year-old Korean woman, who had previously undergone treatment for fallopian tube serous papillary adenocarcinoma, presented with a growing solitary mass in the right liver lobe after treatment. Although CA-125 level was normal, the mass was initially presumed to be metastasis from the primary fallopian tube carcinoma. On further examination, it was shown to be a UESL. Primary liver tumors should be considered in differential diagnoses in patients with fallopian tube cancer who subsequently raised liver tumors. This is particularly important when there is no direct evidence of recurrence of fallopian tube cancer.

Keywords: Fallopian tube carcinoma; Liver tumor; Undifferentiated embryonal sarcoma of the liver

Fallopian tube carcinoma (FTC) is a rare malignancy, comprising about 1% of all female genital tract cancer [1]. Its histologic appearance and clinical behavior resemble that of primary ovarian carcinoma. FTC usually manifests as widespread intraperitoneal metastasis [2]. A few patients are affected by an aggressive disease including liver, lung, or brain metastases [3]. An autopsy study of 428 patients with tubal cancer reported that over 40% of the patients with tubal cancer had evidence of liver metastases at the time of death [4]. Undifferentiated embryonal sarcoma of the liver (UESL), first documented in 1978, is a rare and highly malignant hepatic neoplasm of mesenchymal origin and shows a divergent differentiation [5,6]. UESL is a rare type of tumor and represents only 0.2% of all primary liver tumors [7]. Although UESL is considered a relatively major entity in pediatric liver malignancies, its frequency in the adult population is extremely low. In fact, few reports have focused on the general features of adult cases [8]. Furthermore, the detailed pathological characteristics of adult cases based on particular immuno-histochemistry are not yet clear. To our knowledge, no study has described the systemic pathology features of UESL in this journal. Our patient had received paclitaxel and cisplatin as adjuvant chemotherapy after resection of tubal cancer. Although CA-125 level was normal, Continuous follow-up scans found liver mass. We suspected persistent tubal cancer and performed liver resection. The results of the biopsy turned out to be primary UESL. We also review literature, diagnosis and treatment of UESL.

Case Report

A 41-year-old Korean woman visited our hospital diagnosed with...
Persistant tubal cancer. Although CA-125 level was normal, she had a metastatic hepatic nodule detected by computer tomography (CT) scans and positron-emission tomography-computed tomography (PET-CT) scans. She had visited the local medical hospital two years ago with elevated serum CA-125 level and right adnexal mass on the CT scans. She had no experience in delivery and had a history of left salpingo-oophorectomy and myomectomy ten years and four years ago. Due to tubal pregnancy, the left salpingo-oophorectomy was performed. She had no history of underlying disease and specific family history. At local medical hospital, an exploratory laparotomy was performed. She was diagnosed with a tubal serous adenocarcinoma. Total abdominal hysterectomy, right salpingo-oophorectomy, and total omentectomy were done. Due to tumor invasion, splenectomy and distal pancreatectomy were performed. Final staging revealed IIIc fallopian tube carcinoma. Chemotherapy with cisplatin in combination with decetaxel was started 3 weeks after the operation. She had 9 cycles of first-line chemotherapy after the surgery at that hospital. After two months of first-line chemotherapy, CA-125 level slightly was elevated. We rechecked abdominal-pelvic CT scans and PET-CT scans. These scans showed a newly developed metastatic nodule in hepatic dome and seeding nodules in perihepatic space. New mass was found after two months. She was diagnosed with persistant tubal cancer and treated with 2nd line chemotherapy with cisplatin in combination with paclitaxel. Because chemotherapy was performed at another hospital, we do not know why paclitaxel used as second chemotherapy. Despite the persistant state, they thought doxcltaxel was effective. After 3 cycles treatments of 2nd line chemotherapy, PET-CT scans revealed a nearly complete regression of persistant mass. The serum CA-125 level was within the normal range. After that she wanted to be transferred to our hospital.

She visited our hospital with normal serum CA-125 level and a nearly complete regression of persistant hepatic nodule mass. She was 6 times more chemotherapy at our hospital. But PET-CT scans and CT scans after chemotherapy revealed an aggravating metastatic liver mass in hepatic dome area (Fig. 1). The serum CA-125 level was still within in normal range. She was consulted to hepato-

![Fig. 1.](A) Newly noted metastatic nodule in the right hepatic dome (2010 November 8). (B) Aggravating process of the metastatic mass in the right hepatic lobe (2011 May 10).
tobiliary department. She was performed liver segmentectomy and was diagnosed UESL (Fig. 2). MAID (doxorubicin/ifosfamide/dacarbazine) that she had were based on the experience derived from the treatment of sarcoma. Radiotherapy has been utilized with UESL, especially when surgical margins were not tumor free. Our patient received a successful surgery and was treated with chemoradiation therapy. In presence, She has been followed up with our departments.

Discussion

UESL has a predilection for children and young adults of 20 years than younger. To our knowledge, few cases have been reported in patients over the age of 40 years [8]. The overall clinical outcome is poor with a long term disease-free survival rate of less than 30% in all series. UESL has no specific clinical features. It has been shown that children patients usually have the clinical symptoms of a large palpable mass with or without abdominal pain [9]. Most patients do not complain of nonspecific gastro-intestinal symptoms and signs, such as weight loss, nausea or anorexia, vomiting, jaundice, diarrhea, and fever [10]. Hepatomegaly may be present with large tumors, and liver function tests may be deranged, although frank jaundice is rare [5,11]. The nonspecific nature of the presenting symptoms makes clinical diagnosis extremely difficult without imaging or biopsy. UESL is not related to hepatitis and liver cirrhosis, and the liver function and tumor markers such as alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and CA 19-9 are normal in most cases. In our cases, laboratory tests showed mildly elevated levels of alanine aminotransferase and aspartate aminotransferase.

According to literature, the principal pathological features of UESL in children include an expansive intrahepatic growth with massive necrosis, hemorrhage, and occasional gelatinous appearance [5,6]. Macroscopically, UESL is usually a large, solitary and well-circumscribed mass with variable areas of hemorrhage, necrosis and cystic degeneration. Microscopically, it is composed of loosely arranged, medium-large spindles, oval and stellate pleomorphic

![Fig. 2. A segment of liver (13×8×8 cm, 161 g in toto), It shows whitish friable solid mass with hemorrhage and necrosis, which replaces near-total normal liver.](image1)

![Fig. 3. Microscopic findings. (A) Atypical spindle cells with small and round or large and bizarre nuclei (H&E, ×200). (B) Strong reactivity for vimentin in spindle and polygonal or round cells and focal cytoplasmic positivity for desmin was found in some tumor cells (desmin, ×200).](image2)
cells with poorly defined cell borders, and giant cells with severe atypia. Although it’s pathological origin remains unclear, ultrastructural and immune histochemical studies have shown its fibroblastic, histiocytic, lipoblastic, myoblastic, myofibroblastic, rhabdomyoblastic and leiomyoblastic differentiation [12]. Most UESL are diffusely positive for vimentin, α1-AT, and focally positive for cytokeratin, desmin, α-SMA, muscle-specific actin, CD68, myoglobin, non-specific enolase (Fig. 3), S100, and CD34, suggesting that embryonal sarcoma is an undifferentiated sarcoma, since it may display partial differentiation [12,13]. Although the lesion can be identified on ultrasonography and CT scan, contrast-enhanced magnetic resonance imaging (MRI) scan is the best imaging modality for characterization of UESL. Radiologic characteristics of UESL are enhanced peripheral rim, some solid portions at the periphery or adjacent to the septa, and discrepancy in internal architecture between CT and ultrasound scan [8]. But in recent years contrast-enhanced MRI scan is the best imaging. UESL shows hyperintense signal on T2 weighted MR images with low signal intensity septations. The majority of UESL is located in the right lobe, but it can also arise in the left lobe or in the bilateral lobes simultaneously. UESL in adults should be differentially diagnosed from carcinosarcoma, sarcomatoid or spindle-cell carcinoma, mesenchymal hamartoma, mixed hepatoblastoma with spindle-cell features, angiomylipoma, and various other sarcomas (such as malignant fibrous histiocytoma, leiomyosarcoma, osteosarcoma, angiosarcoma, liposarcoma, melanoma, rhabdomyosarcoma or malignant schwannoma) [12]. Besides its large size, no other specific features can be used in differential diagnosis of UESL from other hepatic masses. However, the morphology and complete immunohistochemical profiles of other hepatic masses are different from those of UESL. The prognosis of UESL is poor. Even after complete resection of the tumor, few UESL patients can achieve a long-term, disease-free survival. Since 1990, long-term survivors after multiagent chemotherapy have been reported and their outcome appears to have improved substantially over the last decades [14]. The chance of cure depends on radical resection and vigorous multiple approaches including chemotherapy [14]. To our knowledge, the current study is the first to demonstrate a significantly improved survival for patients with UESL who received adjuvant chemotherapy after undergoing a complete tumor resection compared with patients who underwent radical tumor resection alone [15]. The use of this treatment strategy was supported by more recent reports on UESL. Although radical surgery remains the mainstay of treatment, recent studies have shown improved survival with radical surgery in addition to the use of ifosamide-based multiagent chemotherapy Thus, in most cases, the accepted standard treatment would consist of aggressive surgical resection and combination with chemotherapy either in neoadjuvant or adjuvant setting [7]. In this patient UESL masqueraded as a metastatic FTC. This case illustrates that the possibility of a primary liver tumor should be considered in patients with FTC who subsequently present with liver tumors, particularly when there is no direct evidence of recurrence of FTC. When we followed up patients with tubal and ovarian cancer, if liver mass does not correspond with CA-125 level, we must doubt primary liver tumor. Treatment should begin as soon as possible.

References

난관암 전이로 오인된 간의 미분화 배아육종의 예

고신의대 복음병원 산부인과
김진하, 이태화, 김흥열, 김원규, 김성한

간에서 생기는 미분화 배아육종은 아주 드물게 보이며 보통 유년기에 발생하고 그 경과가 나쁜 질환이다. 중년기여성에 생긴 미분화 배아육종은 더욱 더 희귀한 예이다. 이전에 난관암으로 항암약물 치료를 받은 41세 여성의 간의 우배엽에 종괴가 발견되었다. CA-125는 정상범위이었지만 지속적으로 커지는 종괴로 인해 난관암의 재발로 생각하고 약물치료를 하였으나, 효과를 보지 못하였다. 종괴를 제거하는 수술을 시행하였고, 간에 생긴 원발성 미분화 배아육종임을 알게되었다. 난관암이나 난소암환자에서 임상과 일치하지 않는 간의 종괴를 발견하게 된다면 수술적 진단을 우선 시행하는 것이 바람직하며, 간의 원발성 종양도 간과해서는 안 될 것이다.

중심단어: 난관암, 간종양, 간 미분화 배아육종

KOREAN JOURNAL OF OBSTETRICS & GYNECOLOGY
Jin Ha Kim, et al. Undifferentiated embryonal sarcoma of the liver (UESL)

2008;15:536-44.